Array
(
[id] => 543
[catid] => 191
[title] => 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 1
[author] => 系统管理员
[status] => 9
[url] => https://www.anes-guide.com/show/543.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.222
[inputtime] => 2024-01-11 15:13:02
[updatetime] => 2024-01-11 15:13:02
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] =>
[demo_url] =>
[zjpjff] => LOE
[zjfj] =>
[tjqd] =>
[nianfen] => 2022
[guojia] => European Society of Cardiology
[pdf] =>
[tjyjyw] =>
[lyyw] => In patients with symptomatic, monomorphic, and sustained VT associated with myocardial scar, recurring despite optimal medical therapy, ablation of arrhythmia is recommended before elective NCS.(Evidence: Level B，Recommendation: Class Ⅰ)
[laiyuan] => 在有症状、单形性和持续性室性心动过速伴心肌瘢痕(尽管采用最佳药物治疗，但仍复发)的患者，推荐在择期非心脏手术前进行心律失常消融。（证据级别：Level B ；推荐强度：Class Ⅰ）
[znzldj] => A
[_inputtime] => 1704957182
[_updatetime] => 1704957182
[_nrjc] =>
[_nrsh] =>
)
推荐意见
在有症状、单形性和持续性室性心动过速伴心肌瘢痕(尽管采用最佳药物治疗，但仍复发)的患者，推荐在择期非心脏手术前进行心律失常消融。（证据级别：Level B ；推荐强度：Class Ⅰ）
In patients with symptomatic, monomorphic, and sustained VT associated with myocardial scar, recurring despite optimal medical therapy, ablation of arrhythmia is recommended before elective NCS.(Evidence: Level B，Recommendation: Class Ⅰ)
证据评价方法：LOE
指南质量等级：A
年份：2022
国家：European Society of Cardiology
Array
(
[id] => 544
[catid] => 191
[title] => 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 1
[author] => 系统管理员
[status] => 9
[url] => https://www.anes-guide.com/show/544.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.222
[inputtime] => 2024-01-11 15:13:02
[updatetime] => 2024-01-11 15:13:02
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] =>
[demo_url] =>
[zjpjff] => LOE
[zjfj] =>
[tjqd] =>
[nianfen] => 2022
[guojia] => European Society of Cardiology
[pdf] =>
[tjyjyw] =>
[lyyw] => Clinical and echocardiographic evaluation (if not recently performed) is recommended in all patients with known or suspected VHD who are scheduled for elective intermediate- or high-risk NCS. (Evidence: Level C，Recommendation: Class Ⅰ)
[laiyuan] => 推荐对所有已知或疑似心脏瓣膜病且计划进行择期中危或高危非心脏手术的患者进行临床和超声心动图评价（如果最近未进行）。（证据级别：Level C ；推荐强度：Class Ⅰ）
[znzldj] => A
[_inputtime] => 1704957182
[_updatetime] => 1704957182
[_nrjc] =>
[_nrsh] =>
)
推荐意见
推荐对所有已知或疑似心脏瓣膜病且计划进行择期中危或高危非心脏手术的患者进行临床和超声心动图评价（如果最近未进行）。（证据级别：Level C ；推荐强度：Class Ⅰ）
Clinical and echocardiographic evaluation (if not recently performed) is recommended in all patients with known or suspected VHD who are scheduled for elective intermediate- or high-risk NCS. (Evidence: Level C，Recommendation: Class Ⅰ)
证据评价方法：LOE
指南质量等级：A
年份：2022
国家：European Society of Cardiology
Array
(
[id] => 545
[catid] => 191
[title] => 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 1
[author] => 系统管理员
[status] => 9
[url] => https://www.anes-guide.com/show/545.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.222
[inputtime] => 2024-01-11 15:13:02
[updatetime] => 2024-01-11 15:13:02
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] =>
[demo_url] =>
[zjpjff] => LOE
[zjfj] =>
[tjqd] =>
[nianfen] => 2022
[guojia] => European Society of Cardiology
[pdf] =>
[tjyjyw] =>
[lyyw] => It is recommended to perform pre-operative screening for hypertension-mediated organ damage and CV risk factors in newly diagnosed hypertensive patients who are scheduled for elective high-risk NCS. (Evidence: Level C ，Recommendation: Class Ⅰ)
[laiyuan] => 推荐对新诊断高血压患者，在拟行择期高危NCS术前进行高血压性器官损害和心血管危险因素的术前筛查。（证据级别：Level C ；推荐强度：Class Ⅰ）
[znzldj] => A
[_inputtime] => 1704957182
[_updatetime] => 1704957182
[_nrjc] =>
[_nrsh] =>
)
推荐意见
推荐对新诊断高血压患者，在拟行择期高危NCS术前进行高血压性器官损害和心血管危险因素的术前筛查。（证据级别：Level C ；推荐强度：Class Ⅰ）
It is recommended to perform pre-operative screening for hypertension-mediated organ damage and CV risk factors in newly diagnosed hypertensive patients who are scheduled for elective high-risk NCS. (Evidence: Level C ，Recommendation: Class Ⅰ)
证据评价方法：LOE
指南质量等级：A
年份：2022
国家：European Society of Cardiology
Array
(
[id] => 546
[catid] => 191
[title] => 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 1
[author] => 系统管理员
[status] => 9
[url] => https://www.anes-guide.com/show/546.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.222
[inputtime] => 2024-01-11 15:13:02
[updatetime] => 2024-01-11 15:13:02
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] =>
[demo_url] =>
[zjpjff] => LOE
[zjfj] =>
[tjqd] =>
[nianfen] => 2022
[guojia] => European Society of Cardiology
[pdf] =>
[tjyjyw] =>
[lyyw] => It is not recommended to defer NCS in patients with stage 1 or 2 hypertension. (Evidence: Level C ，Recommendation: Class Ⅲ)
[laiyuan] => 不推荐推迟1期或2期高血压患者的NCS。（证据级别：Level C ；推荐强度：Class Ⅲ）
[znzldj] => A
[_inputtime] => 1704957182
[_updatetime] => 1704957182
[_nrjc] =>
[_nrsh] =>
)
推荐意见
不推荐推迟1期或2期高血压患者的NCS。（证据级别：Level C ；推荐强度：Class Ⅲ）
It is not recommended to defer NCS in patients with stage 1 or 2 hypertension. (Evidence: Level C ，Recommendation: Class Ⅲ)
证据评价方法：LOE
指南质量等级：A
年份：2022
国家：European Society of Cardiology
Array
(
[id] => 547
[catid] => 191
[title] => 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 1
[author] => 系统管理员
[status] => 9
[url] => https://www.anes-guide.com/show/547.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.222
[inputtime] => 2024-01-11 15:13:02
[updatetime] => 2024-01-11 15:13:02
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] =>
[demo_url] =>
[zjpjff] => LOE
[zjfj] =>
[tjqd] =>
[nianfen] => 2022
[guojia] => European Society of Cardiology
[pdf] =>
[tjyjyw] =>
[lyyw] => Pre-operative routine carotid artery imaging is not recommended in patients undergoing NCS. (Evidence: Level C ，Recommendation: Class Ⅲ)
[laiyuan] => 不推荐接受NCS的患者进行术前常规颈动脉成像。（证据级别：Level C ；推荐强度：Class Ⅲ）
[znzldj] => A
[_inputtime] => 1704957182
[_updatetime] => 1704957182
[_nrjc] =>
[_nrsh] =>
)
推荐意见
不推荐接受NCS的患者进行术前常规颈动脉成像。（证据级别：Level C ；推荐强度：Class Ⅲ）
Pre-operative routine carotid artery imaging is not recommended in patients undergoing NCS. (Evidence: Level C ，Recommendation: Class Ⅲ)
证据评价方法：LOE
指南质量等级：A
年份：2022
国家：European Society of Cardiology
Array
(
[id] => 548
[catid] => 191
[title] => 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 1
[author] => 系统管理员
[status] => 9
[url] => https://www.anes-guide.com/show/548.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.222
[inputtime] => 2024-01-11 15:13:02
[updatetime] => 2024-01-11 15:13:02
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] =>
[demo_url] =>
[zjpjff] => LOE
[zjfj] =>
[tjqd] =>
[nianfen] => 2022
[guojia] => European Society of Cardiology
[pdf] =>
[tjyjyw] =>
[lyyw] => Pre-operative carotid artery and cerebral imaging is recommended in patients with a history of TIA or stroke in the previous 6 months and who have not undergone ipsilateral revascularization. (Evidence: Level C，Recommendation: Class Ⅰ)
[laiyuan] => 对于在过去6个月内有短暂性脑缺血发作或卒中史且未接受同侧血运重建的患者，推荐进行术前颈动脉和脑成像。（证据级别：Level C ；推荐强度：Class Ⅰ）
[znzldj] => A
[_inputtime] => 1704957182
[_updatetime] => 1704957182
[_nrjc] =>
[_nrsh] =>
)
推荐意见
对于在过去6个月内有短暂性脑缺血发作或卒中史且未接受同侧血运重建的患者，推荐进行术前颈动脉和脑成像。（证据级别：Level C ；推荐强度：Class Ⅰ）
Pre-operative carotid artery and cerebral imaging is recommended in patients with a history of TIA or stroke in the previous 6 months and who have not undergone ipsilateral revascularization. (Evidence: Level C，Recommendation: Class Ⅰ)
证据评价方法：LOE
指南质量等级：A
年份：2022
国家：European Society of Cardiology
Array
(
[id] => 549
[catid] => 191
[title] => 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 1
[author] => 系统管理员
[status] => 9
[url] => https://www.anes-guide.com/show/549.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.222
[inputtime] => 2024-01-11 15:13:02
[updatetime] => 2024-01-11 15:13:02
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] =>
[demo_url] =>
[zjpjff] => LOE
[zjfj] =>
[tjqd] =>
[nianfen] => 2022
[guojia] => European Society of Cardiology
[pdf] =>
[tjyjyw] =>
[lyyw] => In patients with known risk factors (age> 65 years, BMI> 30 kg/m2, diabetes, hypertension, hyperlipidaemia, CV disease, or smoking) undergoing intermediate- or high-risk NCS, it is recommended to screen for pre-operative renal disease by measuring serum creatinine and GFR. (Evidence: Level C ，Recommendation: Class Ⅰ)
[laiyuan] => 对于已知有风险因素（年龄 > 65岁、BMI > 30 kg/m2、糖尿病、高血压、高脂血症、心血管疾病或吸烟）且接受中或高风险NCS的患者，推荐通过测量血清肌酐和肾小球滤过率筛查术前肾病。（证据级别：Level C ；推荐强度：Class Ⅰ）
[znzldj] => A
[_inputtime] => 1704957182
[_updatetime] => 1704957182
[_nrjc] =>
[_nrsh] =>
)
推荐意见
对于已知有风险因素（年龄 > 65岁、BMI > 30 kg/m2、糖尿病、高血压、高脂血症、心血管疾病或吸烟）且接受中或高风险NCS的患者，推荐通过测量血清肌酐和肾小球滤过率筛查术前肾病。（证据级别：Level C ；推荐强度：Class Ⅰ）
In patients with known risk factors (age> 65 years, BMI> 30 kg/m2, diabetes, hypertension, hyperlipidaemia, CV disease, or smoking) undergoing intermediate- or high-risk NCS, it is recommended to screen for pre-operative renal disease by measuring serum creatinine and GFR. (Evidence: Level C ，Recommendation: Class Ⅰ)
证据评价方法：LOE
指南质量等级：A
年份：2022
国家：European Society of Cardiology
Array
(
[id] => 550
[catid] => 191
[title] => 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 1
[author] => 系统管理员
[status] => 9
[url] => https://www.anes-guide.com/show/550.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.222
[inputtime] => 2024-01-11 15:13:02
[updatetime] => 2024-01-11 15:13:02
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] =>
[demo_url] =>
[zjpjff] => LOE
[zjfj] =>
[tjqd] =>
[nianfen] => 2022
[guojia] => European Society of Cardiology
[pdf] =>
[tjyjyw] =>
[lyyw] => In patients who have known CVD or CV risk factors (including age≥65 years), or symptoms or signs suggestive of CVD it is recommended to obtain a pre-operative 12-lead ECG before intermediate- and high-risk NCS.(Evidence: Level C，Recommendation: Class Ⅰ)
[laiyuan] => 对于已知有心血管疾病或心血管危险因素（包括年龄≥65 岁），或有心血管疾病症状或体征的患者，推荐在中高风险NCS术前获取12导联心电图。（证据级别：Level C ；推荐强度：Class Ⅰ）
[znzldj] => A
[_inputtime] => 1704957182
[_updatetime] => 1704957182
[_nrjc] =>
[_nrsh] =>
)
推荐意见
对于已知有心血管疾病或心血管危险因素（包括年龄≥65 岁），或有心血管疾病症状或体征的患者，推荐在中高风险NCS术前获取12导联心电图。（证据级别：Level C ；推荐强度：Class Ⅰ）
In patients who have known CVD or CV risk factors (including age≥65 years), or symptoms or signs suggestive of CVD it is recommended to obtain a pre-operative 12-lead ECG before intermediate- and high-risk NCS.(Evidence: Level C，Recommendation: Class Ⅰ)
证据评价方法：LOE
指南质量等级：A
年份：2022
国家：European Society of Cardiology
Array
(
[id] => 551
[catid] => 191
[title] => 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 1
[author] => 系统管理员
[status] => 9
[url] => https://www.anes-guide.com/show/551.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.222
[inputtime] => 2024-01-11 15:13:02
[updatetime] => 2024-01-11 15:13:02
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] =>
[demo_url] =>
[zjpjff] => LOE
[zjfj] =>
[tjqd] =>
[nianfen] => 2022
[guojia] => European Society of Cardiology
[pdf] =>
[tjyjyw] =>
[lyyw] => In patients who have known CVD, CV risk
factors (including age ≥65 years), or symptoms
suggestive of CVD it is recommended to
measure hs-cTn T or hs-cTn I before
intermediate- and high-risk NCS, and at 24 h and
48 h afterwards.(Evidence: Level B ，Recommendation: Class Ⅰ)
[laiyuan] => 对于已知有心血管疾病或心血管危险因素（包括年龄≥65 岁），或有心血管疾病症状或体征的患者，推荐建议在中高危NCS术前、术后后24小时和48小时测定hs-cTnT或hs-cTnI。（证据级别：Level C ；推荐强度：Class Ⅰ）
[znzldj] => A
[_inputtime] => 1704957182
[_updatetime] => 1704957182
[_nrjc] =>
[_nrsh] =>
)
推荐意见
对于已知有心血管疾病或心血管危险因素（包括年龄≥65 岁），或有心血管疾病症状或体征的患者，推荐建议在中高危NCS术前、术后后24小时和48小时测定hs-cTnT或hs-cTnI。（证据级别：Level C ；推荐强度：Class Ⅰ）
In patients who have known CVD, CV risk
factors (including age ≥65 years), or symptoms
suggestive of CVD it is recommended to
measure hs-cTn T or hs-cTn I before
intermediate- and high-risk NCS, and at 24 h and
48 h afterwards.(Evidence: Level B ，Recommendation: Class Ⅰ)
证据评价方法：LOE
指南质量等级：A
年份：2022
国家：European Society of Cardiology
Array
(
[id] => 552
[catid] => 191
[title] => 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 1
[author] => 系统管理员
[status] => 9
[url] => https://www.anes-guide.com/show/552.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.222
[inputtime] => 2024-01-11 15:13:02
[updatetime] => 2024-01-11 15:13:02
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] =>
[demo_url] =>
[zjpjff] => LOE
[zjfj] =>
[tjqd] =>
[nianfen] => 2022
[guojia] => European Society of Cardiology
[pdf] =>
[tjyjyw] =>
[lyyw] => In patients who have known CVD, CV risk factors
(including age ≥65 years), or symptoms suggestive
of CVD, it should be considered to measure BNP
or NT-proBNP before intermediate- and high-risk
NCS. (Evidence: Level B ，Recommendation: Class IIa)
[laiyuan] => 对于已知心血管疾病、心血管危险因素(包括年龄≥65岁)或有心血管疾病症状的患者，应考虑在中高危NCS术前测定BNP或NT-proBNP。（证据级别：Level B ；推荐强度：Class IIa）。
[znzldj] => A
[_inputtime] => 1704957182
[_updatetime] => 1704957182
[_nrjc] =>
[_nrsh] =>
)
推荐意见
对于已知心血管疾病、心血管危险因素(包括年龄≥65岁)或有心血管疾病症状的患者，应考虑在中高危NCS术前测定BNP或NT-proBNP。（证据级别：Level B ；推荐强度：Class IIa）。
In patients who have known CVD, CV risk factors
(including age ≥65 years), or symptoms suggestive
of CVD, it should be considered to measure BNP
or NT-proBNP before intermediate- and high-risk
NCS. (Evidence: Level B ，Recommendation: Class IIa)
证据评价方法：LOE
指南质量等级：A
年份：2022
国家：European Society of Cardiology
